Pharmaceutical giant faces a growing list of questions from investors and regulators
News comes as Canadian drug-maker pulled 2016 forecasts
Chief executive back at the helm after two-month absence through illness but Robert Ingram retains chairman’s post
Company says bid fails to properly value business
US investment firm last week lowered its bid for the drugmaker to $11.25 a share from an earlier $12 per share offer
YOU MAY ALSO LIKE...
How does a post-Brexit world shape the identity and relationship of these islands
Inquests into the nightclub fire that led to the deaths of 48 people
Weddings, Births, Deaths and other family notices